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Abstract 
COVID-19 is a complex disease involving immunological, vascular, and metabolic 
pathology caused by and consequences of beta-coronavirus SARS-CoV-2 infection. 
One may use Sun Tzu analogy of war to fight COVID-19 and to survive infection.  
When enemy has not reached the shore, gathering much intelligence is key to know 
how the enemy moves and who would be the most vulnerable targets of enemy attacks. 
Physical distancing, massive nucleic acid testing, and identification of comorbidity 
may prepare for the incoming enemies. Physical distancing has helped to limit 
transmission of the virus that mainly is due to close contacts with droplets coughed off 
infected individuals. Moreover, aerosolized virus particles may also contribute to 
spreading. Nucleic acid testing using real time PCR platform has been a diagnostic 
gold standard to identify infected individuals during early stage of infection. On the 
other hand, serological test to capture antibody against SARS-CoV-2 may be useful 
for immunosurveillance.  Discovery of human ACE2 (angiotensin converting enzyme) 
protein as an obligate partner of SARS-CoV-2 viral entry has provided insights to 
mechanisms of serious post-infection ramifications to individuals having 
comorbidities such as hypertension, diabetes or heart conditions.  When the enemy 
reaches ashore, thorough profiling of biomarkers involved in inflammation and 
coagulation (IL-6, lymphopenia, ground glass opacity, d-dimers, thrombocytopenia) 
may help predict disease progression and guide treatment strategy. While estimated 
80% of infected individuals may recover on their own, the remaining 20% may require 
hospitalization and serious therapeutic intervention. Several clinical trials are 
underway such as repurposing existing drugs and evaluating efficacy of convalescence 
plasma therapy. Finally, vaccine development using genetic engineering may also help 
control the global spread if it is proven effective. 
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 Coronavirus disease 2019 or COVID-19 has claimed 
many lives and globally has not gone unabated. Started 
in late December 2019, COVID-19 has been described 
as an unusual pneumonia affecting initially people who 
had attended and traded in wet animal market in Wuhan.1 
Soon thereafter the causative viral agent has been 
identified and its genomic sequence has been made 
public. The RNA virus is named SARS-CoV-2 because 
its genomic homology to SARS-CoV-1, a beta 
coronavirus that causes SARS (Severe Acute 
Respiratory Syndrome) in 2002-2004.2 Moreover, just 
like SARS-CoV-1, SARS-CoV-2 also recognizes and 
binds human ACE2 (Angiotensin Converting Enzyme). 
Unlike SARS that had been controlled within 8 months 
after infecting 8,100 people in selected territories, 
COVID-19 has spread globally within just 5 months 
infecting 2.6 million people and has overwhelmed health 
care facilities worldwide3 and sometimes claimed many 
lives of professional healthcare workers.4 As of 29th of 
June 2020, there are over 10 million laboratory-
confirmed cases worldwide with more than 0.5 million 
deaths.  
 As the details of COVID19 have continued to be 
unfolded, this review article aims to provide some key 
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coronavirus associated diseases namely SARS and 
MERS and helps giving an overview of challenges in 
controlling the disease. 
 
BATTLE PLAN 
 Imagery of fighting SARS-Cov-2, causative agent of 
COVID-19 invokes the sight of an all-out 
immunological war pitting human hosts against invisible 
invading pathogens. However, immunology also tells us 
that knowing when and how to fight is key to curb 
transmission. Moreover, the ultimate outcome of any 
battle against pathogens is to avoid fatal outcome and to 
minimize long-term morbidity amongst survivors. 
Efforts to curb COVID-19 pandemic do require multi-
pronged approaches and should have awareness about 
timing and stages of disease progression. Not only 
knowing how to clear infection but also how to survive 
infections. This is where mapping out battle plan is 
essential to guide concerted effort about when and how 
to fight.  
 The battle plans may draw up two scenarios mainly 
based on enemy movement. First, when the enemy has 
not reached a shore, gathering intelligence is key. Since 
COVID-19 outbreak has initiated in China, many 
countries have formed defensive positions. At this stage, 
intelligence gathering is critical to address the following 
questions. What is the causative agent of COVID-19? 
What does COVID-19 do to the body? How does SARS-
CoV-2 spread among the people? How to detect 
individuals infected with SARS-CoV-2? However, once 
the enemy has breached defensive lines, the second 
scenario would implement combinatory efforts of 
clearing viral infection and building up immune 
tolerance. In addition, vulnerable individuals such as 
those with hypertension, diabetes, obesity and certain 
heart comorbidities should be paid close attentions for 
getting worst clinical outcome 
 
FIRST SCENARIO: Keeping the enemy at Bay 
 “If you know the enemy and know yourself, you need 
not fear the result of a hundred battles” (Sun Tzu, The 
Art of War). 
 Even though there is already strong association 
between the presence of viral RNA of SARS-CoV-2 and 
clinical symptoms of COVID-19 (fever, dry cough, 
myalgia, malaise, loss of smells, ground glass opacity) 
5,6 formal proof to demonstrate causality is needed. 
SARS-CoV-1 has been defined as a causative agent of 
SARS because it has fulfilled Koch Postulate in mouse 
model expressing human ACE2 (Angiotensin 
Converting Enzyme) receptors.7 Fulfillment of Koch 
Postulate is important to build confidence in 
development of diagnostic, preventive, and treatment 
strategies.  
 
A. What is the causative agent of COVID-19? 
 In case of COVID-19, several laboratories have used 
many approaches to prove causality of SARS-CoV-2 
infection and appearance of the disease. First, transgenic 
mice that express human ACE2 have been made using 
transgenic cassette,8 or gene editing.9 Adenoviral 
infection carrying human ACE2 is another strategy to 
introduce human ACE2,10 an important receptor 
required for SARS-CoV-2 entry. Second, transgenic 
mice expressing human ACE2 have been challenged with 
SARS-CoV-2 viral particles and the results show many 
recapitulations of human diseases.8,10 Pulmonary edema 
and massive leucocytes infiltration have been observed 
consistently in infected human ACE2 transgenic mice. 
Furthermore, peaks of viral load have been observed and 
virus particles have been recovered from the infected 
lungs within few days that mimic human 
pathophysiology of COVID-19. 8,10 These phenotypes are 
not found in wild type mice that do not express human 
ACE2 in spite of deliberate SARS-CoV-2 infection 
proving exquisite specificity. These key results fulfill 
Koch postulate and provide theoretical foundation to 
design diagnostic strategy, discover novel drugs, and 
elucidate molecular pathology.11 Moreover, these ACE2 
mice will serve as preclinical models to test putative or 
novel antiviral drugs and vaccine efficacy.  
 While SARS-CoV-2 is now firmly established as a 
causative agent of COVID-19, there was a lingering 
question “where does it come from”? The zoonotic origin 
of COVID-19 has been implicated by high genomic 
homology or 96% identity between SARS-CoV-2 and bat 
coronavirus.12 To address many speculations that SARS-
CoV-2 was a man-made manipulation, a careful 
structural genomic analyses of the receptor binding 
domain (RBD) of Spike SARS-CoV-2 has been 
performed.2 The results show that there are many 
mutations in the Spike RBD of SARS-CoV-2 that diverge 
from SARS-CoV-1, a coronavirus that causes SARS. In 
spite of the large genetic divergence, both RBDs from 
these coronaviruses are able to bind human ACE2. 
Moreover, several experiments have confirmed these 
specific binding and demonstrated even higher affinity of 
SARS-CoV-2 RBD to ACE2 than SARS-CoV-1.13-14 
Therefore, these genetic and biochemical data has put to 
rest the possibility of the virus being a man-made 
creation.2 Furthermore, many laboratories have 
continued to search for animal reservoirs of SARS-CoV-
2 and explored the possibility of genomic 
recombination’s either within bat coronaviruses15 or with 
other coronaviruses belonging to pangolin or other 
unidentified animals.16 These studies may pave better 
understanding of zoonotic disease evolution and 
transmission to human.  
 
B. What does SARS-CoV-2 do to the body  
 COVID-19 patients also show some abnormal 
immunological and vascular profiles that relate to 
pathological inflammation and coagulation. Relatively 
high circulating interleukin-6 (IL-6), high NLR 
(neutrophils to leucocytes ratio), lymphopenia, presence 
of radiological ground glass opacity, high d-dimers, 
thrombocytopenia, and low platelet counts.12 Recent 
series of autopsy studies on deceased COVID-19 patients 
also show high prevalence of fatal pulmonary thrombo-
embolism, diffuse alveolar damage and presence of viral 
RNA in lung parenchyme.17-20 Some studies also suggest 
cytopathic endothelial damage and abnormal blood 
vessel formations.21  
 
C. Tracking enemy movement (Modes of SARS-CoV-
2 transmission) 
 SARS-CoV-2 has similar characteristics with SARS-
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respectively)  in terms of genetic backbone (that is 
homologous to bat coronaviruses genome), spillover 
zoonotic infection leading to human to human 
transmission, and shared clinical symptoms (dry cough, 
myalgia, fever, gastrointestinal and pulmonary 
involvements).22 However, there are notable differences 
such as high transmission or Ro reproduction numbers 
(2.5, 2.4, and 2 for SARS-CoV-2, SARS-CoV-1, MERS-
CoV, respectively). Rapid timing to reach peaks of viral 
load (SARS-CoV-2 takes 3 to 5 days while SARS-CoV-
1 7 to 10 days), high affinity to ACE2 receptor (SARS-
CoV-2  is 10 times higher than SARS-CoV-1) and 
SARS-CoV-2 tropism to upper respiratory organs (while 
SARS-CoV-1 is mostly in lower respiratory organs) 
(22). Collectively, these unique features make SARS-
CoV-2 transmission more difficult to control and 
consequently more infectious than SARS-CoV-1 and 
MERS-CoV. 
 Close examination of spike proteins of SARS-CoV-
2 may also explain efficient viral transmission when 
compared to SARS-CoV-1. Spike proteins contain 
receptor binding domain (RBD) that is important to bind 
human proteins that is essential for viral binding and 
fusion. Spike proteins of SARS-CoV2 has ten times 
higher affinity to bind human ACE2 receptor than 
SARS-CoV-1.13 Furthermore, there is a short insertion 
of four polybasic amino acids within Spike protein that 
serve as furin binding sites that allow efficient fusion to 
human cells.23,24 Recent in vitro analysis of SARS-CoV-
2 spike protein also demonstrated that G614 variant may 
infect human cells more efficiently and produce higher 
numbers of viral particles than D614 variant.25 The 
change from Aspartic acid to Glycine at codon 614 may 
lead to efficient virus to human cell fusion. This result 
has been proposed to explain the predominance and viral 
existence of D614 variant in North America and Europe. 
However, this putative explanation of G614 variant of 
SARS-CoV-2 rapid transmission does not correlate with 
COVID-19 severity (26).  
 SARS-CoV-2 transmission is largely through close 
contacts when droplets of infected individuals are picked 
up by other individuals. Other studies suggest that some 
medical procedures in hospitals may also create aerosols 
that may carry virus particle in the environments.27 In 
public settings, the use of face masks has been highly 
recommended to prevent transmission. Since SARS-
Cov-2 viral load may build up rapidly in upper 
respiratory organs of individuals with or without mild 
symptoms, contact tracing is essential and deployment 
of proper diagnostic is a must. Recently, the prospect of 
airborne transmission of the virus raise serious issue 
after the description of viral transmission in a restaurant 
in Guangzhou and an incident of choir practice in the 
United States attended by 60 people leaving 33 
confirmed cases and 2 deaths.28,29 These incidents 
outline the risk of airborne transmission due to gathering 
of human activity in enclosed space for hours.  
 In addition to proper diagnostic to halt virus 
transmission, there are three public health policy models 
to control COVID-19. First, comprehensive lockdown 
has been practiced by China in order to halt public 
mobility for several weeks and discourage viral 
transmission.30 Second, massive RTPCR testing has 
been implemented by South Korea to identify and 
confirm every possible suspect of SARS-CoV-2 
carriers.31 Lastly, encouragement of public gathering for 
young people and limiting vulnerable population (elderly 
population and people with comorbidity) has been 
enacted in Sweden.32 The first two models have led to 
‘flattening the curve’ where new cases have been halted. 
On the other hand, Sweden experience has ended up with 
highest mortality rates amongst Nordic countries who 
implemented strict measures of public mobility.33-34 
 
D. How to detect the enemy 
 Publications of SARS-CoV-2 genome have also 
prompted global efforts to design RTPCR test and 
dissemination of RTPCR diagnostic kits.35,36 Primary aim 
of COVID-19 is to break chain of transmission by 
identifying individuals who are infected with SARS-
CoV-2. Individuals with confirmed RTPCR results 
would be isolated in order to protect population at large 
from getting infections. Secondly, diagnostics may help 
to monitor recovery of COVID-19 patients by detecting 
the presence of viral RNA in the patient bodies.37 Patients 
who are in the path of recovery may be tested two times 
with RTPCR within two days. When the RTPCR results 
show two negative results in two consecutive days, 
patients are eligible to be discharged.38 However, this 
protocol may be modified in some countries who adopt 3 
weeks monitoring of clinical parameters as readout of 
recovery since shortage of RTPCR may be allocated to 
perform contact tracing of infected individuals.   
 There are three steps in COVID-19 diagnosis: 
preanalytical, analytical, and post analytical steps. To 
avoid diagnostic  inaccuracy, care must be given during 
pre-analytical step which include specimen collection 
from ideal anatomical sites,  specimen preservations and 
rapid and robust RNA extractions.39,40 Nasopharyngeal 
and oropharyngeal specimens are usually collected 
together from suspected individuals who are at risk of 
contracting the virus due travel history to or from 
epidemic areas, close contact with confirmed cases of 
COVID-19, or appearance of symptoms. Recently, saliva 
may also serve as alternative samplings and has been 
demonstrated to have similar accuracy to conventional 
samplings with less risk to healthcare workers.41 
Asymptomatic or pre-symptomatic individuals are also a 
concern because up to 50% infected individuals do not 
appear to be sick.42 Yet, studies have shown that viral 
loads are high in these individuals rendering transmission 
is likely.  
 Specimen preservation especially from remote areas 
must reach laboratory using proper VTM and 
temperatures to prevent viral RNA degradation. Lastly, 
RNA extraction can become bottleneck in RTPCR 
procedures, especially when there is shortage of RNA 
extraction reagents due to high demands from laboratory 
performing high volume testing. Therefore, automated 
RNA extraction is preferable to obtain consistent results. 
Alternatively, direct RTPCR protocol has been proposed 
to skip RNA extraction step and speed up testing 
procedures.43 
 During analytical step, the choice of methods and 
analyte is important. Due to backlog of RTPCR testing, 
some countries have used lateral flow-based antibody 
testing that has rapid turnaround time, typically 
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point of care testing requiring as little as a drop of blood. 
Although some governments have deployed this tactic, 
emerging literatures show that rapid antibody testing that 
seek to detect anti-viral spike proteins of SARS-CoV-2 
antibodies may not be appropriate to perform diagnostic 
due to low sensitivity in early phase of infections, where 
virus particle is at the highest.44 During this early phase, 
infected individuals may transmit the virus to others 
while they have not developed antibodies against the 
virus, which typically appear 7 to 14 days after first onset 
of symptoms. Reported diagnostic sensitivity of lateral 
flow test during early infection phase is between 20-
40%.44,45 In comparison, RTPCR based testing 
diagnostic sensitivity is between 60-70%. Due to this 
low sensitivity the use lateral-flow based diagnostics is 
highly discouraged except in the setting of clinical 
validation or immunosurveillance studies to estimate the 
burden of infection within certain community or 
territory. Semiquantitative reversed transcriptase real 
time RTPCR is currently a gold standard to detect RNA 
of SARS-CoV-2. Sample collection must be taken 
within less than 5 days after first symptoms appear. Most 
RTPCR primers are targeting ORF1, RDRP, and N 
genes of SARS-CoV-2 where the mutations in these 
regions are relatively rare i.e. less than 1%.46  
 
E. To isolate source of infections 
 COVID-19 outbreak in cruise ship Diamond Princess 
shows the importance of contact tracing and extend 
RTPCR testing to asymptomatic individuals. Japanese 
authority reports that at the end of massive RTPCR 
testing of all passengers and crews demonstrated that 
asymptomatic individuals contribute up to 50% of total 
RTPCR confirmed cases.47 Furthermore, many studies 
have found risk of viral transmission by asymptomatic 
individuals to susceptible individuals (48, 49). 
 
F. To monitor recovery of COVID-19 patients  
 As disease progresses, majority of COVID-19 
patients have shown clinical improvement and 
demonstrated low to undetectable viral RNA. While 
some nasopharyngeal swabs of recovering patients are 
standard methods to monitor viral burdens, some studies 
suggest performing rectal swab RTPCR.50,51 Viable viral 
particles have been recovered from fecal specimens and 
support the possibility of fecal oral transmission. 
Environmental monitoring also shows presence of viral 
RNA in waste centers and toilets where patients are 
being treated.40 There are also concerns that previously 
recovered individuals may get disease recurrence 
although the symptoms may be milder than the initial 
infection.52 Nevertheless, to resolve the issues of 
‘reinfection’, ‘recurrence’ or technical difficulties in 
specimen collection may not be easy in these individuals 
(53). 
 
SECOND SCENARIO: Meeting enemy at the gate 
(viral clearance and/or immune tolerance) 
A. Initial phase of infection 
 Infection of SARS-CoV-2 begins with binding of 
viral Spike protein to human ACE2 receptor. Upon 
binding, human serine protease TMPRSS2 cleaves off 
S1 subunit of viral Spike protein exposing S2 subunit 
which initiates fusion to host cell membranes leading to 
invagination and endocytosis.23 Up to 80% of infected 
individuals who have either asymptomatic to mild or 
moderate symptoms, viral infections are cleared early 
and effectively. Fusion of viral particles and release of 
viral RNA trigger a series of immune activation namely 
Pattern Recognition Receptor (PRR) leading to 
interferons production. Interferon pathway is a major 
innate immunity defense mechanism to clear viral 
infection through recruitment of macrophages, 
neutrophils and natural killer cells.54 In addition, dying or 
apoptotic infected cells are phagocytosed by 
macrophages and initiated the release of pro-
inflammatory cytokines such as IL-1, TNF alpha and IL-
6 promoting further recruitment of immune cells. Direct 
uptake of viral particles or indirect by phagocytosis of 
dying cells by dendritic cells or professional Antigen 
Presenting Cells (APC) will initiate activation of adaptive 
immune cells. APC loads and presents epitope (antigenic 
peptides) of viral particle to T helper cells and activates 
them. T helper cells then promote differentiation of 
antibody producing B cells and cytotoxic CD8 T cells.54 
Combination of viral specific antibody production and 
activation of circulating cytotoxic T cells are important 
to ward off future infection. Successful control of viral 
infection is also shown by the declining amount of viral 
RNA and the appearance of IgG anti SARS-CoV-2. 
 Majority of individuals who survive the initial phase 
of infection often show no symptoms or at best mild 
symptoms requiring no hospitalization. Interestingly, 
antibody titers against SARS-CoV-2 that are being 
generated in these individuals for some unknown reasons 
are low and not sustained at high level, especially when 
compared to COVID-19 patients with serious 
conditions.55 It is not clear whether recovery from 
infections is determined either from certain level of high 
plasma neutralizing antibodies or activation of adaptive 
immunity that is driven by circulating memory T-cells. 
At this stage, neither viral burden nor neutralizing 
antibody predict recovery of infections. 
 There are also some anecdotal reports that individuals 
who have recovered from COVID-19 remain vulnerable 
to another infection, although the clinical manifestation 
is usually mild. Moreover, there is also a need for long 
term surveillance amongst survivors because there is a 
risk to develop diabetes, lung fibrosis, and lung 
cancers.56,57 ACE2 is also expressed in pancreatic cells 
producing insulin and SarS-CoV-2 infection may induce 
apoptosis and compromise the ability to produce insulin. 
The appearance of ground glass opacity in the lung may 
also implicate some degree of inflammation that has long 
term health consequences such as breathing and 
promotion of lung tumorigenesis. 
 Children and individuals with O blood type are 
having better position to avoid severe COVID-19. Some 
have suggested that children tend to have “high” level of 
ACE2 expression which may save them from getting 
uncontrolled inflammation.58 Although ACE2 is an 
essential receptor for SARs-CoV-2 infection, ACE2 is an 
important enzyme to convert Angiotensin 2 (pro 
inflammatory and vasoconstrictor) into Angiotensin 1-7 
(anti-inflammatory and vasodilator).59 Therefore, high 
ACE2 expression actually helps maintain ‘anti 
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 In contrast to children, elderly population is 
particularly susceptible to COVID-19 and has high risk 
of morbidity and mortality. The expression of ACE2 has 
been thought to be lower in aging adults than children. 
Although low ACE2 expression being SARS-CoV-2 
obligate receptor may intuitively confer less 
susceptibility to infection, post infection actually leads 
to internalization of surface ACE2 expression leading to 
aggravation of hypertension and inflammation(60). Old 
age is also associated with immune-senescence and 
inflame-aging, a combination leading to inability to clear 
viral infection effectively.61 Furthermore, the prevalence 
of comorbidities such as diabetes, cardiovascular 
diseases, and hypertension are more common in old 
age.62  
 Blood type O is also found to have the lowest risk of 
severe infections than other blood type, especially blood 
type A as demonstrated by clinical study in China and 
genome wide screening data in Europe (63, 64). The 
protective effect of type O blood is related to the 
presence of anti A antibodies which target certain 
glycosylated antigens. This protective factor is also 
found during SARS. Heavily glycosylated Spike protein 
of SARS-CoV-2 like SARS-CoV-1 are needed to bind 
ACE2 in order to initiate infection. However, anti A 
antibody targeting glycosylated peptide may also 
interfere with effective binding of spike to ACE2 hence 
conferring some protection.65 
 Since pneumonia is one of the COVID-19 hallmarks, 
underlying respiratory diseases affecting lung 
physiology such as chronic obstructive 
pulmonary disease (COPD) and lung cancer are 
expected to confer high risk of morbidity and/or 
mortality. Recent study and meta-analysis review indeed 
confirm the expectation that COVID-19 patients with 
COPD have poor prognosis than patients without 
COPD.66,67 High fatality rate in COVID-19 patients with 
lung cancer has been observed recently.68 Therefore, 
extra precautionary measures must be placed to protect 
individuals with lung diseases from contracting COVID-
19. 
 There is another speculation that national 
programmed of BCG vaccination may protect some 
community against COVID-19.69 Northern America and 
Western Europe who do not mandate BCG vaccination 
are relatively hard hit compared to some Asian nations 
who are still running obligatory BCG vaccination. The 
protective mechanism of previous vaccination against 
COVID-19 invoke the concept of ‘trained immunity’, 
where non-specific immunity against unrelated 
pathogens may induce some resistance to other 
pathogens (70). However, the role of BCG vaccination 
has been challenged recently and calls for prospective 
study to clear up the debates.71 
 
B. Second phase of viral infection 
 For the remaining 20% of infected individuals, viral 
clearance is either unsuccessful and/or ending up with 
futile inflammation known as cytokine storms.72 Like 
COVID-19 predecessors SARS and MERS, 
inflammation also triggers pulmonary coagulopathy and 
occasionally disseminated intravascular coagulation.73,74 
When SARS-CoV-2 enters the respiratory organs, ACE2 
expressing alveolar epithelial cells are the virus main 
targets. In addition, pulmonary vasculatures that are 
made up of ACE2 expressing endothelial cells are also 
susceptible to SARS-CoV-2 infection. Ensuing 
endothelial damages, pro coagulation thrombins are 
released and initiate coagulation cascades as shown in 
high level of d-dimers and low level of platelet counts 
(thrombocytopenia) which are associated with severe 
COVID-19 cases and mortality risk. Therefore, when left 
unchecked, thrombi formation may impede pulmonary 
blood circulation leading to hypoxia and compromising 
oxygen exchange.75  
 Studies on severe and critical COVID-19 patients also 
reveal abnormal immunological reads out.76 Pro 
inflammatory IL-6 is found to be elevated and explain 
high burden of immune infiltration in the lung 
exacerbating tissue damage. High IL-6 is also consistent 
with lymphopenia, where there is a drop of circulating 
lymphocytes. Lymphocytes reduction may be explained 
by two mechanisms. Lymphocytes may leave circulation 
to enter alveolar spaces creating tissue damages.21 
Alternatively, SARs-CoV-2 may directly infect and kill 
lymphocytes through CD147 (77). In spite of having have 
low level expressions of ACE2, lymphocytes remain 
sensitive to SARCoV2 infection, because spike proteins 
of SARS-CoV-2 have 10 times higher affinity to bind 
Ace2 than SARS-CoV-1. 
 Therefore, there is a therapeutic challenge for patients 
who are undergoing the next phase of infection where 
there is a dangerous liaison between inflammatory self-
injury and ongoing viral presence. While high viral 
burden may predict progression to severe cases of 
COVID-19, reduction of viral burden in itself may not 
lead to automatic recovery.78 
 Therefore, aggressive measures to block viral entry or 
replication may seem futile once the disease has become 
progressive into severe symptoms. Clinical trials of 
hydroxychloroquine which aims to block viral entry by 
increasing pH of the endosome has been shown to be 
ineffective in severe COVID-19 patients. Acidic 
endosomes have been thought to be important to 
assemble viral proteins to produce virions. Although in 
vitro data suggest successful blocking of SARS-CoV-2 
by hydroxychloroquine,79 WHO SOLIDARITY80 
clinical trial has announced to stop HC arm based on 
interim analysis demonstrating lack of benefit. Another 
trial in Brazil also shows unacceptable HC toxicity in 
severe COVID-19 patients.81 
 Combinations of protease inhibitors Ritonavir and 
Lopinavir have been used to treat HIV patients. Viral 
proteases are also required for proper assembly of virus 
particles. However, recent clinical trial also fails to 
demonstrate benefit.82 Lastly, antiviral drug remdesivir, 
which is an adenosine analogue to interfere with SARS-
CoV-2 RDRP enzyme during viral RNA replication also 
has mixed results.83 Randomized clinical trial in China 
fails to show statistically significant benefit of remdesivir 
(84). However, another RCT has shown that remdesivir 
may induce some clinical improvement in the 
preliminary report.85 
 Convalescence plasma (CP) therapy is an example to 
control viral infection in severe cases of COVID-19.86 
The idea of CP rests on the assumption that individuals 
who are recovered from COVID-19 may contain levels 
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help current patients to control viral burden. CP has been 
used during SARS with some inconclusive results 
because SARS itself has been controlled fairly quickly. 
There are some case reports of few patients with severe 
COVID-19 who are recovered when given CP. A large 
retrospective study from China also reports clinical 
improvement.87 However, recent meta-analysis has 
demonstrated the difficulty to draw conclusion of CP 
efficacy due to lack of clear results obtained from 
existing randomized clinical trial.88 Recent clinical trial 
has been discontinued due to difficulty to recruit severe 
patients as subjects, ironically as a result of successful 
lockdown.89  
 Interim analyses of the Chinese RCT shows that 
there is a consistent reduction of viral burden that is 
estimated from the Ct value of RT PCR.89 Ct values 
under 15 is generally indicative of high viral burden. 
Both severe and critical patients receiving CP show 
consistent reduction of viral burden after treatment. 
However, this reduction does not associate directly with 
clinical improvement.89 It is not clear whether failure to 
see CP efficacy is due to lack or insufficient level of 
neutralizing antibody (Nab) in CP donors. In fact, studies 
on neutralizing antibody dynamic show that severe 
COVID-19 patients have higher level of Nab than 
individuals who have recovered from COVID-19. 
Therefore, much to be learned to explain why some 
severe patients do get clinical improvement after CP 
therapy. 
 Another innovative approach to block SARS-CoV-2 
virus infection is inject soluble recombinant human 
ACE2.90 There are two reasons why this approach may 
work as supported by recent successful preclinical data 
on animal model expressing human ACE2. First, the 
soluble ACE2 may act like decoy and biological sink to 
attract SARS-CoV-2.91 Second, the circulating ACE2 
may capture and convert Angiotensin 2 into Ang 1-7. 
Infection of SARS-CoV-2 may cause downregulation of 
endogenous ACE2 leading to elevated levels of Ang 2 
which promote inflammation.92 Injection of soluble 
ACE2 may control and bring down Ang2. 
 While antiviral studies have not yield conclusive 
efficacy to treat COVID-19, drugs to control 
inflammation and/or maintain physiological function 
such as blood pressure and blood glucose have shown 
some benefits. 
 
Controlling inflammation (immune tolerance) 
 Generally, reducing inflammation in viral infected 
individuals runs risk of getting secondary bacterial or 
nosocomial infections. IL-6 is one of the inflammatory 
cytokines that is consistently upregulated and may serve 
as predictor of severe COVID-19 cases.  Tocilizumab is 
a monoclonal antibody targeting IL-6 that is currently 
undergoing clinical trial in severe COVID-19 cases.93 
BTK inhibitor is another example of repurposing drug 
that is originally given as anti-cancer drugs. The 
inhibitor targets the cells that are expressing IL-6 at high 
levels.94  
 Recovery Clinical Trial in the United Kingdom 
shows that Dexamethasone may reduce mortality risk to 
30% in severe cases of COVID-19 but not in mild cases 
(95, 96). Dexamethasone, a well-known anti-
inflammatory drug with plethora of side effects may not 
be an ideal drug but the results show that reducing 
inflammatory burden is as important as viral clearance. 
 
Controlling coagulation 
 Pulmonary coagulopathy and occasionally 
disseminated intravascular coagulation have been 
observed in COVID-19 patients.74,97,98 Autopsy reports 
also show that the majority of fatal COVID-19 cases have 
shown abnormal coagulation especially in the lung. 
However, giving blood thinner or anti-coagulant may 
also run risk of bleeding. Therefore, timing to give blood 
thinner must be paid close attention. Several clinical trials 
are ongoing to see the effect of anti-coagulations.99,100 
 
Controlling blood pressure 
 Hypertension has been identified as a risk factor 
associated with severe case of COVID-19.101 This is due 
to generally lack or reduced level of ACE2 expression in 
hypertensive, diabetic, and some patients with cardiac 
conditions.102 ACE2 is one of the homeostasis regulator 
of RAS system renin-angiotensin-aldosterone system. 
Angiotensin 2, a substrate of ACE2 is a potent 
vasoconstrictor and inducer of inflammations. ACE2 is 
converting Angiotensin 2 into Angiotensin 1-7 that has 
opposite effect to Ang2 i.e. vasodilators and anti-
inflammation. While hypertensive and diabetic patients’ 
risk of infection is identical to individuals who have no 
comorbidities, hypertension and diabetic poses 
significant risk to get a severe case of COVID-19. 
Hypertensive and diabetic patients have already risk of 
being high inflammatory status and prone to undergo 
cytokine storms.102 
 Since SARS-CoV-2 binds to ACE2, there are 
concerns that hypertensive patients may be at risk to have 
higher susceptibility to be infected when they do not stop 
consuming hypertension drugs. The concern is based in 
animal studies where treatments of  ACE (angiotensin 
converting enzyme) inhibitor or ARB (angiotensin 
receptor blockers) lead to elevated expression of 
ACE2.103,104 However, recent studies show that the 
consumptions of ACEi and ARB by hypertensive patients 
are not associated with higher risk of mortality and 
morbidity than those who do not consume.105-107 In one 
study, anti-hypertensive drug consumption may actually 
associate with better clinical outcome.108 Therefore, 
whether there is an unintended benefit of ACEi and ARB 
to improve COVID-19 outcome should be tested in RCT. 
Meanwhile American Heart Association has 
recommended patients to continue with their 
hypertensive medications even when diagnosed with 
COVID-19.109 
 
Controlling blood glucose 
 Recent gene expressions study suggest that diabetic 
patients may have been associated with high level 
expression of ACE2, receptors for SARS-CoV-2 Spike 
proteins.110 Moreover, hyperglycemia commonly found 
in diabetic patients may also induce ACE2 expression. 
Whether elevated ACE2 expression correlates with high 
burden of SARS-CoV-2 virus remain to be seen. 
However, diabetic patients do have some inflammation 
within their vascular system. Therefore, infection of 
SARS-CoV-2 may exacerbate the already pro 
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patients. Interestingly, COVID-19 patients with diabetes 
may have higher chance of survival when they are able 
to control their blood sugar.111 
 
TOWARD END OF A PANDEMIC? 
 ‘The supreme art of war is to subdue the enemy 
without fighting.’ (Sun Tzu) 
 Through strict public health policy measures, SARS 
and MERS have been eliminated in matter of months 
with much less victims than what COVID-19 has 
claimed to date. This rapid elimination could also be 
attributed to high case fatality rate of SARS and MERS 
ie 10% and 30%, respectively. Therefore, victims who 
fall ills are relatively easy to be identified and isolated.  
However, complete elimination of SARS and MERS has 
left substantial gaps in our knowledge about pathogenic 
coronavirus behavior. Vaccines against SARS and 
MERS have not been developed forcing the scientific 
community to start developing COVID-19 from scratch.  
 Fortunately, the advance of bioinformatics and speed 
of Next Generation Sequencing have helped warp-speed 
the production of modern vaccines such as DNA/RNA 
vaccines and recombinant antigens that are relatively 
inexpensive than the traditional approach making 
vaccine seed using inactivated or weakened virus 
approach.112,113 However, though initial production of 
vaccine seeds may take short time, there is a hurdle of 
testing the efficacy of these variety of vaccines in 
protecting the population from future infections.  
 There are several concerns about how to prove 
vaccine efficacy.114 First, individuals who have mild or 
asymptomatic COVID-19 and are recovered from 
COVID-19 do not have sustainable level of antibody.55 
Therefore, the putative protection conferred by the 
vaccines should be described in detail regarding the level 
and sustainability of neutralizing antibody being 
generated, the production of mucosal immunity to 
intercept the virus in respiratory organs and the presence 
of memory T cells. Secondly, vaccines that produce low 
or insufficient level of neutralizing antibody may lead to 
ADE (antibody dependent enhancement) of SARS-
COV-2 infection with worst symptoms. These low levels 
anti SARS-COV-2 antibody being produced by poorly 
validated vaccine forms immune complex with actual 
virus. These unintentional immune complex formations 
may illicit violent immune response mediated by Fc 
gamma receptors of the innate immune cells.115 
Moreover, innate immunity would be inadvertently a 
target of infection themselves compromising the first 
line of defenses against incoming viruses. Although 
ADE has been well described in Dengue Hemorrhagic 
Fever, ADE in SARS-CoV-2 has not been documented. 
However, ADE remains a theoretical possibility due to 
the speed of vaccine development which may have risk 
of overlooking the details of vaccine validation before 
rolling it out to the population. 
 
CONCLUSIONS 
 COVID-19 pandemic has taught many lessons 
regarding our state of knowledge. Apparently neither 
existing knowledge nor experiences are able to stop the 
global reach of COVID-19 transmission. Apparently, 
medical intervention alone is insufficient but must 
involve social cooperation such as physical distancing 
and personal hygiene. The relatively high viral burden 
without necessarily showing symptoms does contribute 
to the rapid transmission. Therefore, innovation in point-
of-care diagnostics is key to identify the enemy as early 
as possible. The complex inflammatory and coagulation 
impact of COVID-19 must be understood in detail in 
order to mount precise treatment and patient 
stratification.99 Complete biomarkers profiling using 
comprehensive molecular tools could be important to 
predict patients who are most likely to recover or 
progress to withstand cytokine storms. However, there is 
opportunity for global cooperation to advance scientific 
understanding of drug discovery and vaccine 
development. At the end of the day, human body of 
knowledge and resilience will prevail, and we shall pay 
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